Effects of hemodialysis on plasma oxylipins.
dialysis
eicosanoids
fatty acids
lipidomics
oxylipins
Journal
Physiological reports
ISSN: 2051-817X
Titre abrégé: Physiol Rep
Pays: United States
ID NLM: 101607800
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
28
01
2020
revised:
04
04
2020
accepted:
24
04
2020
entrez:
21
6
2020
pubmed:
21
6
2020
medline:
2
7
2021
Statut:
ppublish
Résumé
Chronic kidney disease (CKD) is an important risk factor for cardiovascular and all-cause mortality. Survival rates among end-stage renal disease (ESRD) hemodialysis patients are poor and most deaths are related to cardiovascular disease. Oxylipins constitute a family of oxygenated natural products, formed from fatty acid by pathways involving at least one step of dioxygen-dependent oxidation. They are derived from polyunsaturated fatty acids (PUFAs) by cyclooxygenase (COX) enzymes, by lipoxygenases (LOX) enzymes, or by cytochrome P450 epoxygenase. Oxylipins have physiological significance and some could be of regulatory importance. The effects of decreased renal function and dialysis treatment on oxylipin metabolism are unknown. We studied 15 healthy persons and 15 CKD patients undergoing regular hemodialysis treatments and measured oxylipins (HPLC-MS lipidomics) derived from cytochrome P450 (CYP) monooxygenase and lipoxygenase (LOX)/CYP ω/(ω-1)-hydroxylase pathways in circulating blood. We found that all four subclasses of CYP epoxy metabolites were increased after the dialysis treatment. Rather than resulting from altered soluble epoxide hydrolase (sEH) activity, the oxylipins were released and accumulated in the circulation. Furthermore, hemodialysis did not change the majority of LOX/CYP ω/(ω-1)-hydroxylase metabolites. Our data support the idea that oxylipin profiles discriminate ESRD patients from normal controls and are influenced by renal replacement therapies.
Identifiants
pubmed: 32562348
doi: 10.14814/phy2.14447
pmc: PMC7305238
doi:
Substances chimiques
Oxylipins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14447Informations de copyright
© 2020 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.
Références
J Biosci. 2007 Mar;32(2):279-91
pubmed: 17435320
Adv Nutr. 2015 Sep 15;6(5):513-40
pubmed: 26374175
J Altern Complement Med. 2017 Aug;23(8):632-638
pubmed: 28375641
Physiol Rep. 2020 Jan;8(2):e14332
pubmed: 31981323
Am J Physiol Heart Circ Physiol. 2019 Jun 1;316(6):H1468-H1479
pubmed: 30951365
Pulm Pharmacol Ther. 2002;15(1):25-33
pubmed: 11969361
Physiol Rep. 2019 Jul;7(13):e14165
pubmed: 31304687
Acta Pharmacol Sin. 2018 Jul;39(7):1142-1154
pubmed: 29877318
Clin Nephrol. 2020 Jan;93(1):1-8
pubmed: 31599226
Prog Lipid Res. 2004 Jan;43(1):55-90
pubmed: 14636671
Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:8-17
pubmed: 22922020
Front Pharmacol. 2014 Jan 07;4:176
pubmed: 24432004
Cardiovasc Toxicol. 2019 Aug;19(4):365-371
pubmed: 30725262
Prostaglandins Other Lipid Mediat. 2016 Sep;125:108-17
pubmed: 27287720
Life Sci. 1990;46(6):427-33
pubmed: 2304379
Sci Transl Med. 2011 Feb 9;3(69):69ra12
pubmed: 21307302
Circ J. 2013;77(7):1807-16
pubmed: 23585488
Life Sci. 1987 Jan 19;40(3):225-31
pubmed: 3796222
Int Urol Nephrol. 2012 Dec;44(6):1799-804
pubmed: 22127406
Metabolomics. 2018 Aug 1;14(8):104
pubmed: 30830362
Am J Physiol Heart Circ Physiol. 2011 Jun;300(6):H1990-6
pubmed: 21398593
Resuscitation. 2008 Jan;76(1):89-94
pubmed: 17728042
Hypertension. 2002 Feb;39(2 Pt 2):609-13
pubmed: 11882617
J Exp Med. 2014 Jul 28;211(8):1673-87
pubmed: 25049337
Int J Cardiol. 2013 Oct 9;168(4):3647-51
pubmed: 23711456
Free Radic Biol Med. 2019 Apr;134:598-603
pubmed: 30743046
Basic Res Cardiol. 2000;95 Suppl 1:I72-6
pubmed: 11192357
Pharmacol Ther. 2018 Mar;183:177-204
pubmed: 29080699
Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):54-60
pubmed: 18927469
Oncotarget. 2015 Sep 22;6(28):24699-708
pubmed: 26322503
Pharmacol Rep. 2010 May-Jun;62(3):468-74
pubmed: 20631410
Nephrol Dial Transplant. 1990;5(11):937-41
pubmed: 2127829
Ther Adv Endocrinol Metab. 2018 May;9(5):137-150
pubmed: 29796244
Biochim Biophys Acta. 2015 Apr;1851(4):356-65
pubmed: 25093613
Physiol Rep. 2020 Jun;8(12):e14447
pubmed: 32562348
Mater Med Pol. 1992 Oct-Dec;24(4):241-2
pubmed: 1308052
J Lipid Res. 2014 Jun;55(6):1150-64
pubmed: 24634501
Physiol Rev. 2002 Jan;82(1):131-85
pubmed: 11773611
Prostaglandins Leukot Essent Fatty Acids. 2004 May;70(5):475-8
pubmed: 15062851
Physiol Rep. 2019 Apr;7(8):e14040
pubmed: 31016868
Pflugers Arch. 2010 May;459(6):881-95
pubmed: 20224870
Nephron. 1984;37(4):250-6
pubmed: 6379485
Circ Res. 1996 Mar;78(3):415-23
pubmed: 8593700
Immunology. 1980 Aug;40(4):709-19
pubmed: 6776039
J Biol Chem. 1985 Dec 25;260(30):16056-9
pubmed: 3934168
Cardiovasc Res. 1988 Mar;22(3):213-8
pubmed: 3167945
Nephrol Dial Transplant. 2020 Feb 1;35(2):303-312
pubmed: 30137494
Am J Pathol. 1989 Mar;134(3):671-6
pubmed: 2538061
Exp Physiol. 2007 Nov;92(6):1067-76
pubmed: 17675416
Chem Phys Lipids. 1996 Jul 30;82(1):39-51
pubmed: 8810050
J Am Soc Nephrol. 2017 Oct;28(10):2845-2855
pubmed: 28701518
Stroke. 2008 May;39(5):1593-6
pubmed: 18323494
J Immunol. 1980 May;124(5):2100-4
pubmed: 6767782
Cell Immunol. 1980 Sep 1;54(2):390-401
pubmed: 6774816
J Biol Chem. 1997 Nov 21;272(47):29546-53
pubmed: 9368016
J Physiol. 2001 Aug 1;534(Pt 3):651-67
pubmed: 11483698
Am J Physiol Heart Circ Physiol. 2011 Oct;301(4):H1311-8
pubmed: 21821782
Kidney Int. 2011 Jan;79(1):57-65
pubmed: 20962739
Prostaglandins Other Lipid Mediat. 2012 Aug;98(3-4):91-3
pubmed: 22178722
Am J Physiol. 1991 Oct;261(4 Pt 1):C623-33
pubmed: 1928326